A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected With HIV.

Trial Profile

A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected With HIV.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2013

At a glance

  • Drugs Cabotegravir (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Sep 2013 Results published in HIV Clinical Trials.
    • 09 Oct 2009 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
    • 14 Sep 2009 Results were reported at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top